izpis_h1_title_alt

An LC-MS/MS method for quantification of lamotrigine and its main metabolite in dried blood spots
ID Milosheska, Daniela (Avtor), ID Roškar, Robert (Avtor), ID Vovk, Tomaž (Avtor), ID Lorber, Bogdan (Avtor), ID Grabnar, Iztok (Avtor), ID Trontelj, Jurij (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (2,87 MB)
MD5: CA6DA12A4BC76D6FD2F8E3C8F133899F
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1424-8247/17/4/449 Povezava se odpre v novem oknu

Izvleček
Background: The antiepileptic drug lamotrigine (LTG) shows high pharmacokinetic variability due to genotype influence and concomitant use of glucuronidation inducers and inhibitors, both of which may be frequently taken by elderly patients. Our goal was to develop a reliable quantification method for lamotrigine and its main glucuronide metabolite lamotrigine-N2-glucuronide (LTG-N2-GLU) in dried blood spots (DBS) to enable routine therapeutic drug monitoring and to identify altered metabolic activity for early detection of drug interactions possibly leading to suboptimal drug response. Results: The analytical method was validated in terms of selectivity, accuracy, precision, matrix effects, haematocrit, blood spot volume influence, and stability. It was applied to a clinical study, and the DBS results were compared to the concentrations determined in plasma samples. A good correlation was established for both analytes in DBS and plasma samples, taking into account the haematocrit and blood cell-to-plasma partition coefficients. It was demonstrated that the method is suitable for the determination of the metabolite-to-parent ratio to reveal the metabolic status of individual patients. Conclusions: The clinical validation performed confirmed that the DBS technique is a reliable alternative for plasma lamotrigine and its glucuronide determination.

Jezik:Angleški jezik
Ključne besede:dried blood spot, lamotrigine, lamotrigine glucuronide, therapeutic drug monitoring, clinical validation, haematocrit effect
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:16 str.
Številčenje:Vol. 17, art. 449
PID:20.500.12556/RUL-155604 Povezava se odpre v novem oknu
UDK:615.015:616.853
ISSN pri članku:1424-8247
DOI:10.3390/ph17040449 Povezava se odpre v novem oknu
COBISS.SI-ID:191424771 Povezava se odpre v novem oknu
Datum objave v RUL:08.04.2024
Število ogledov:93
Število prenosov:8
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Pharmaceuticals
Skrajšan naslov:Pharmaceuticals
Založnik:MDPI
ISSN:1424-8247
COBISS.SI-ID:517582617 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:epileptični napadi, farmakokinetika, posušena krvna lisa, lamotrigin, lamotrigin glukuronid, terapevtsko spremljanje zdravil, klinična validacija, učinek hematokrita

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0189
Naslov:Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Ad Futura Scientific and Educational Foundation of the Republic of Slovenia

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj